Feb 25, 2021
Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV(TM) (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
Feb 22, 2021
FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of >=50%
Feb 16, 2021
Orsini Specialty Pharmacy Selected To Be The Exclusive Specialty Pharmacy Partner For Evkeeza(TM) (evinacumab-dgnb)
Feb 12, 2021
The Lancet Publishes Libtayo® (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of >=50%
Feb 11, 2021
U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation
Feb 01, 2021
New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting
Jan 26, 2021
Regeneron Reports Positive Interim Data with REGEN-COV(TM) Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
Jan 21, 2021
Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021
Jan 12, 2021
Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
Dec 29, 2020
Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
Dec 16, 2020
Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference
Nov 30, 2020
Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting
Nov 21, 2020
Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
Nov 16, 2020
Regeneron Included on Dow Jones Sustainability World Index for Second Consecutive Year
Nov 05, 2020
Regeneron Reports Third Quarter 2020 Financial and Operating Results
Oct 28, 2020
Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
Oct 06, 2020
Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020
Sep 29, 2020
Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients
Sep 21, 2020
Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of >=50%
Sep 18, 2020
Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO